Georg Kettschau

USPTO Granted Patents = 17 (Patent Applications = 12)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 12 (Patent Applications = 23)

Average Co-Inventor Count = 7.8

ph-index = 2

Forward Citations = 14(Granted Patents)

Company Filing History:

6 out of 192

Bayer Schering Pharma Ag

patents

6 out of 378

Bayer Pharma Aktiengesellschaft

Bayer Intellectual Property Gmbh

Years Active: 2008-2019

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10487092 - Pyrazolopyridinamines as MKNK1 and MKNK2 inhibitors (2019-11-26),

2. 9675612 - Substituted thiazolopyrimidines (2017-06-13),

3. 9556181 - Substituted pyrazolopyrimidinylamino-indazoles (2017-01-31),

4. 9540392 - Thienopyrimidines (2017-01-10),

5. 9382255 - Substituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase inhibitors (2016-07-05),

6. 9314540 - Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system (2016-04-19),

7. 9296757 - Substituted benzothienopyrimidines (2016-03-29),

8. 9238631 - Radiolabeled amino acids for diagnostic imaging (2016-01-19),

9. 8642611 - Alkynylpyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same (2014-02-04),

10. 8481539 - Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same (2013-07-09),

11. 8003655 - Substituted sulphoximines as TIE2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same (2011-08-23),

12. 7846928 - Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same (2010-12-07),

13. 7842809 - Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same (2010-11-30),

14. 7825128 - Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs (2010-11-02),

15. 7825114 - Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same (2010-11-02),

Title: The Innovator Extraordinaire: Georg Kettschau

Introduction:

Georg Kettschau, a visionary inventor based in Berlin, DE, has made significant contributions to the tech landscape with his innovative ideas and groundbreaking patents. His relentless pursuit of excellence and passion for innovation have set him apart as a true pioneer in the field.

Latest Patents:

Kettschau's latest patents showcase his expertise and focus on developing compounds for the treatment of various diseases. One of his patents involves Pyrazolopyridinamines as MKNK1 and MKNK2 inhibitors, offering a promising avenue for the treatment of hyperproliferative and angiogenesis disorders, as well as inflammatory diseases. Another patent highlights his work on Substituted thiazolopyrimidines, demonstrating his dedication to advancing pharmaceutical compositions for the treatment of hyperproliferative and angiogenesis disorders.

Career Highlights:

With an impressive portfolio of 17 patents, Georg Kettschau has established himself as a leading inventor in the industry. Throughout his career, he has made substantial contributions to companies such as Bayer Schering Pharma Ag and Bayer Pharma Aktiengesellschaft. His innovative ideas and research have paved the way for advancements in pharmaceuticals and healthcare.

Collaborations:

Kettschau has collaborated with esteemed professionals in the field, including Philip Lienau and Hans Briem. These collaborations have not only enriched his projects but have also fostered a culture of teamwork and shared expertise in the pursuit of groundbreaking innovations.

Conclusion:

In conclusion, Georg Kettschau's dedication to innovation and his groundbreaking work in developing novel compounds for disease treatment have established him as a pioneer in the global tech landscape. His patents reflect his commitment to pushing the boundaries of what is achievable in the field of pharmaceuticals, inspiring future generations of inventors to think boldly and drive positive change.

This text is generated by artificial intelligence and may not be accurate.